Search results
Showing 361 to 375 of 672 results for diabetes
This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.
This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.
This guideline covers the period before, during and after a young person moves from children's to adults' services. It aims to help young people and their carers have a better experience of transition by improving the way it’s planned and carried out. It covers both health and social care.
This guideline covers the care of women with a singleton pregnancy at increased risk of, or with symptoms and signs of, preterm labour (before 37 weeks), and women with a singleton pregnancy having a planned preterm birth. It aims to reduce the risks of preterm birth for the baby and describes treatments to prevent or delay early labour and birth.
Chronic heart failure in adults: diagnosis and management (NG106)
This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.
Urinary tract infection (catheter-associated): antimicrobial prescribing (NG113)
This guideline sets out an antimicrobial prescribing strategy for catheter-associated urinary tract infection in children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.
NICE makes 4 types of recommendation that allow us to produce clear, directive, actionable guidance that is easy to understand and put into practice.
Evidence-based recommendations on gastroelectrical stimulation for gastroparesis. This involves using a stimulating device to send electrical impulses to the stomach muscles to help them work normally.
Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.
monitoring in adults with type 1 diabetes. Source guidance details Comes from guidance Type 1 diabetes in adults: diagnosis...
children and young people with type 1 diabetes. Source guidance details Comes from guidance Diabetes (type 1 and type 2) in...
Inhaled insulin for the treatment of type 1 and type 2 diabetes (TA113)
In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete. Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications. 25 January 2008
Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]
Discontinued Reference number: GID-TA10236
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
Antisocial behaviour and conduct disorders in children and young people (QS59)
This quality standard covers recognising and managing antisocial behaviour and conduct disorders in children and young people. It describes high-quality care in priority areas for improvement.
View quality statements for QS59Show all sections
Sections for QS59
- Quality statements
- Quality statement 1: Early intervention
- Quality statement 2: Comprehensive assessment
- Quality statement 3: Improving access to services
- Quality statement 4: Parent or carer training
- Quality statement 5: Multimodal interventions
- Quality statement 6: Monitoring adverse effects of pharmacological interventions
- Update information